General Information
AstraZeneca NASH Phase 1
A Phase 1, Double Blind, Randomised, Placebo-controlled, Multi-centre Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients with Non-alcoholic Steatohepatitis (NASH) with Fibrosis Stage 1-3 and Homozygous for the PNPLA3 148M Risk Allele
| Protocol | D7830C00002 |
|---|---|
| Identifier | |
| UID | 66a37e63-ffba-43d2-b216-45a0e3c626da |
| Status | Done - Archived |
| Phase | 1 |
| Category | NASH / Adult |
| Launch Year | 2021 |
| NCT Number | - |
| Created | 2020-11-19 11:59 |
| Last Updated | 2024-04-02 20:02 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2021-04-19 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2021-02-17 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2024-03-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | - | No | |
| Coordinator | Gallardo, Michael | MGallardo | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | AstraZeneca Pharmaceuticals |
|---|---|
| Division | AstraZeneca Pharamecuticals |
| Team | AstraZeneca Pharamecuticals LP |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Parexel International |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
